{"id":"W3179720171","doi":"10.1089/dia.2021.0108","title":"Immunogenicity of the novel glucagon analog dasiglucagon: Results of a dedicated immunogenicity trial in type 1 diabetes","year":2021,"lang":"en","type":"article","venue":"Diabetes Technology & Therapeutics","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Immunogenicity; Medicine; Hypoglycemia; Clinical endpoint; Type 1 diabetes; Glucagon; Diabetes mellitus; Subcutaneous injection; Type 2 diabetes; Internal medicine; Randomized controlled trial; Incidence (geometry); Clinical trial; Insulin; Antibody; Immunology; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002189028,0.0006423211,0.001062243,0.0001517218,0.0002276113,0.0004272957,0.0002856611,0.0005618318,0.000976535],"category_scores_gemma":[0.001324966,0.0001847906,0.000853318,0.0001611301,0.0005186363,0.0003480731,0.0002641129,0.001245143,0.0001749951],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003212497,"about_ca_system_score_gemma":0.0004546759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002056636,"about_ca_topic_score_gemma":0.0002631794,"domain_scores_codex":[0.9993345,0.0004066075,0.00003871384,0.0000812625,0.00005599592,0.00008289831],"domain_scores_gemma":[0.9989533,0.0003184269,0.0002052541,0.0001505549,0.00006129185,0.0003109791],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7931882,0.04276814,0.006934761,0.0003504108,0.000908487,0.0002247061,0.0002381043,0.001478189,0.06049802,0.0001464528,0.0006678877,0.09259657],"study_design_scores_gemma":[0.1454184,0.8238007,0.01780883,0.00001994178,0.0004758927,0.0003034785,0.00004601454,0.0009216403,0.01024479,0.00009861031,0.000842815,0.00001895151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990251,0.0003476535,0.0001367263,0.00004207189,0.00001888172,0.0001067623,0.00004890852,0.000008099293,0.0002657512],"genre_scores_gemma":[0.9982388,0.0003259287,0.0004429298,0.0001349912,0.00008717119,0.0001456329,0.0002745453,0.000005398696,0.0003446251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002189028,"threshold_uncertainty_score":0.01157683,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05339899138269436,"score_gpt":0.3356627159685671,"score_spread":0.2822637245858727,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}